UA99638C2 - Оксазолидиноны для лечения и/или профилактики сердечной недостаточности - Google Patents

Оксазолидиноны для лечения и/или профилактики сердечной недостаточности

Info

Publication number
UA99638C2
UA99638C2 UAA201008619A UAA201008619A UA99638C2 UA 99638 C2 UA99638 C2 UA 99638C2 UA A201008619 A UAA201008619 A UA A201008619A UA A201008619 A UAA201008619 A UA A201008619A UA 99638 C2 UA99638 C2 UA 99638C2
Authority
UA
Ukraine
Prior art keywords
heart failure
prophylaxis
treatment
oxazolidinones
disorders related
Prior art date
Application number
UAA201008619A
Other languages
English (en)
Ukrainian (uk)
Inventor
Харальд КАЛЛАБИС
Вольфганг ТИЛЕМАНН
Элизабет ПЕРЦБОРН
Сусанне Рериг
Дагмар Кубитца
Теодоре Спиро
Ллойд Хаскелл
Джит МАХАЛ
Original Assignee
Баер Шеринг Фарма Акциенгезельшафт
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баер Шеринг Фарма Акциенгезельшафт, Янссен Фармацевтика Н.В. filed Critical Баер Шеринг Фарма Акциенгезельшафт
Publication of UA99638C2 publication Critical patent/UA99638C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение касается применения соединения формулы (I) для лечения и/или профилактики сердечной недостаточности.
UAA201008619A 2007-12-11 2008-12-03 Оксазолидиноны для лечения и/или профилактики сердечной недостаточности UA99638C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US740607P 2007-12-11 2007-12-11

Publications (1)

Publication Number Publication Date
UA99638C2 true UA99638C2 (ru) 2012-09-10

Family

ID=40404481

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201008619A UA99638C2 (ru) 2007-12-11 2008-12-03 Оксазолидиноны для лечения и/или профилактики сердечной недостаточности

Country Status (18)

Country Link
US (1) US20110003804A1 (ru)
EP (1) EP2229173A1 (ru)
JP (1) JP2011506363A (ru)
KR (1) KR20110010689A (ru)
CN (1) CN101896185A (ru)
AU (1) AU2008335922A1 (ru)
BR (1) BRPI0820964A2 (ru)
CA (1) CA2708418C (ru)
DO (1) DOP2010000156A (ru)
IL (1) IL205675A (ru)
MA (1) MA31902B1 (ru)
MX (1) MX2010005545A (ru)
NZ (1) NZ586002A (ru)
RU (2) RU2494740C2 (ru)
SV (1) SV2010003578A (ru)
TN (1) TN2010000266A1 (ru)
UA (1) UA99638C2 (ru)
WO (1) WO2009074249A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905760T3 (es) * 2009-07-31 2022-04-12 Krka D D Novo Mesto Procedimientos para la cristalización del rivaroxabán
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
US20200200774A1 (en) * 2017-06-20 2020-06-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for identifying whether patients with acute decompensated heart failure (adhf) exhibit a hypercoagulable state
KR20200080309A (ko) * 2017-11-09 2020-07-06 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법
JP6574041B2 (ja) * 2017-12-15 2019-09-11 エルメッド株式会社 リバーロキサバン含有医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE146783T1 (de) * 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
ES2134870T3 (es) * 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra

Also Published As

Publication number Publication date
CA2708418C (en) 2013-11-12
RU2013134140A (ru) 2015-01-27
KR20110010689A (ko) 2011-02-07
TN2010000266A1 (en) 2011-11-11
AU2008335922A1 (en) 2009-06-18
BRPI0820964A2 (pt) 2015-07-14
CN101896185A (zh) 2010-11-24
IL205675A (en) 2013-10-31
SV2010003578A (es) 2011-02-21
RU2494740C2 (ru) 2013-10-10
IL205675A0 (en) 2010-11-30
US20110003804A1 (en) 2011-01-06
MX2010005545A (es) 2010-07-30
MA31902B1 (fr) 2010-12-01
RU2010128442A (ru) 2012-01-20
EP2229173A1 (en) 2010-09-22
DOP2010000156A (es) 2011-02-15
WO2009074249A1 (en) 2009-06-18
JP2011506363A (ja) 2011-03-03
NZ586002A (en) 2012-06-29
CA2708418A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
GB0625648D0 (en) Compounds
IN2012DN01233A (ru)
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
HK1146485A1 (ru)
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
UA105036C2 (ru) Аминотетралиновые производные, фармацевтическая композиция, содержащая их, и их применение в терапии
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
NO20091655L (no) Substituerte dihydropyrazoloner for behandling av kardiovaskulaere og hematologiske sykdommer
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
NO20084328L (no) Nye forbindelser
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2009013501A (es) Compuestos piperidinicos y sus usos.
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
JO2645B1 (en) Vehicles
MY150931A (en) Substituted oxazolidinones and their use
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung